Abstract
The apelinergic system has been receiving clinical attention in recent years due to its pathophysiological relationships with the renin-angiotensin system and the possibility of potential modification of this system by targeted therapeutic intervention.

This bioactive peptide and G-protein receptor can be a target site for therapy for cardiovascular system diseases such as heart failure, arterial and pulmonary hypertension, atherosclerosis, diabetes mellitus type 2, and possibly also preeclampsia and septic shock. The presented review provides an up-to-date view of the relationship between the apelin system and cardiovascular alterations, as well as the view on the possibilities of its therapeutic modulations of the apelin system in several cardiovascular pathologies, concerning the possibility of reducing the still high cardiovascular morbidity and mortality (Tab. 1, Fig. 3, Ref. 50). Text in PDF www.lekarsky.herba.sk.
KEY WORDS: apelin, elabela, renin-angiotensin, pharmacotherapy.
Lek Obz 2024, 73 (7): 242-247

Andrej DUKÁT 1, Juraj PAYER 1, Helena ŠTEFANIČKOVÁ 1, Ján KYSELOVIČ 1, Peter JACKULIAK 1, Patrik VALENT 1, Marián BERNADIČ 3, Peter STANKO 3, Fedor ŠIMKO 3

1 V. interná klinika LF UK a UNB v Bratislave, prednosta prof. MUDr. J. Payer, PhD., MPH, FRCP, FEFIM
2 Institute of Science and Technology, Austria
3 Ústav patologickej fyziológie LF UK v Bratislave, prednosta prof. MUDr. F. Šimko, PhD., FRCP